Company Now in Position to Roll-Out Its U.S. Strategy

Proceeds to Enhance Marketing to Accelerate Ablatherm-HIFU RPP Business in Europe

Clear Global Leader in Prostate Cancer HIFU Continues Market Acceleration Strengthening Its Position by Adding New RPP Sites

Mobile RPP Utilization Increasing, New Centers Added; Strong Commitment from Distribution Partne

Ablatherm-HIFU Tours to Accelerate HIFU Adoption for Prostate Cancer, Add New Users and Sites EDAP Marketing Programs Driving Patient Inquiries, Moving Doctors to Action

Europe's RPP Program: On Track to Group Profitability The USA: EDAP's New and Exciting Opportunity

HIFU Utilization Increasing as Company Accelerates Its Growth Program Company Adding Resources to Launch RPP Centers More Quickly

EDAP and HealthTronics in Discussions Realigning US Market Entry; Ablatherm RPP Success Growing Europe; Lithotripsy Returns to Profitability - Solid Cash Position for Continued Growth

European RPP Program on Target for 2008 Profitability; FDA Trial Launch Positions EDAP for Direct USA Control; EDAP, China Medical Alliance Unites HIFU Leaders

Record Fourth Quarter Revenue Financial Highlights: Full year revenues of Euro 22.2 million, up 10% year-over-year Record fourth quarter revenue of Euro 7.0 million, up 43% year-over-year Robust 42% full year revenue attributed to Ablatherm-HIFU Ablatherm-HIFU RPP treatments increased 36% year-over-year; 40% from fourth quarter 2006 Approximately 3,400 Ablatherm-HIFU treatments worldwide for year, yielding 15,000 cumulative treatments at 176 clinical sites Successful launch of integrated Sonolith I-Sys for the disintegration of urinary stones